marked.bio

Company

Black Diamond Therapeutics

2 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

silevertinib 2

Trials

2 of 3 trials shown

  1. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

    Recruiting Phase 2 Black Diamond Therapeutics Started 2026Primary completion 2028-11 NCT07326566

    silevertinibtemozolomide

    For Part 1 (Safety Lead-in) ONLY: EGFR alterations.

    EGFR exon 19 deletion / L858RGlioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)

  2. Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

    Active, not recruiting Phase 1/2 Black Diamond Therapeutics Started 2022Primary completion 2025-11 NCT05256290

    silevertinib

    …ed resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third ge…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer